hVIVO (LON:HVO) Share Price Crosses Above 50-Day Moving Average – Time to Sell?

hVIVO plc (LON:HVO)’s share price passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of GBX 7.81 and traded as high as GBX 9.10. hVIVO shares last traded at GBX 8.95, with a volume of 1,271,796 shares traded.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on HVO. Shore Capital Group reiterated a “buy” rating on shares of hVIVO in a research report on Wednesday, April 22nd. Stifel Nicolaus restated a “hold” rating and issued a GBX 10 target price on shares of hVIVO in a research note on Thursday, May 7th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of GBX 15.

hVIVO Trading Down 2.8%

The stock’s 50 day simple moving average is GBX 7.81 and its 200 day simple moving average is GBX 7.13. The firm has a market cap of £59.89 million, a PE ratio of -10.00 and a beta of 1.69. The company has a debt-to-equity ratio of 38.75, a quick ratio of 1.16 and a current ratio of 1.63.

hVIVO (LON:HVO) last posted its quarterly earnings data on Wednesday, April 15th. The company reported GBX (0.87) earnings per share for the quarter. hVIVO had a negative net margin of 12.48% and a negative return on equity of 14.65%. The company had revenue of GBX 4,677 million for the quarter. On average, sell-side analysts forecast that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other hVIVO news, insider Brendan Buckley sold 2,017,000 shares of the firm’s stock in a transaction dated Friday, April 24th. The stock was sold at an average price of GBX 9, for a total transaction of £181,530. 4.95% of the stock is owned by insiders.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.